Key facts
- Animol Discovery’s last known valuation is $68.0M (Jul 2022).
- It has raised $50.5M across 2 recorded rounds; the latest was Seed Round ($4.0M) in Nov 2024.
- Notable investors include Novalis LifeSciences, Anterra Capital, DYDX, Finistere Ventures.
- Animol Discovery has filed 2 Form Ds with the SEC since 2022, most recently Dec 2024 ($4.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Animol Discovery
Funding rounds
2 roundsAbout Animol Discovery
Developer of animal drug discovery technology designed to discover small-molecule active pharmaceutical ingredients. The company's technology builds on DNA-encoded chemicals to allow a substantially accelerated ultra-high throughput screening process and evaluate target and anti-target activities, enabling veterinarians to provide proper pet treatments.
- Sector
- Business Products and Services (B2B)
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 16
- Website
- animol-discovery.com/
- Ownership
- Privately Held (backing)
Animol Discovery doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Animol Discovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Animol Discovery in its N-PORT filings yet. We sweep new filings monthly.